Effectiveness of Two Silicone Dressings for Sacral and Heel Pressure Ulcer Prevention
Primary Purpose
Pressure Ulcer
Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Mepilex® Border Sacrum and Mepilex® Border Heel
Sponsored by
About this trial
This is an interventional other trial for Pressure Ulcer focused on measuring Skin, safety, wounds, intensive care
Eligibility Criteria
- Major trauma patients and/or critically ill patients (e.g. with cardiac arrest) admitted to the emergency department and being transferred and/or admitted directly to a surgical or internal ICU
Being at "high" or "very high" PU risk according to the Charité PU prevention standard:
- Category 3 (= partly care dependent/limited mobility in bed), 4A (= care depended, limited mobility in bed), 4B (= totally immobile) according to the Jones classification modified by Charité
- Expected minimum length of stay at least three days
- Informed consent (or by legal representative)
Sites / Locations
- Charité-Universitätsmedizin Berlin
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Mepilex® Border
Control
Arm Description
If a patient is assigned to the intervention group the dressings Mepilex® Border Sacrum and Mepilex® Border Heel will be applied onto the respective intact skin areas in addition to standard pressure ulcer prevention
Standard pressure ulcer prevention according to hospital standard
Outcomes
Primary Outcome Measures
Number of Pressure Ulcers Category II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum (Proportion)
The primary outcome was the cumulative incidence of Pressure ulcer category II, III, IV, unstageable and DTI at heels or sacrum. Pressure ulcers were categorized according to the NPUAP/EPUAP 2014 classification System. The occurrence of a new pressure ulcer of any category was assessed and documented daily during the study period. The Categories are defined as follows: Category I (nonblanchable erythema); Category II (Partial thickness Skin loss); Category III (Full Thickness Skin loss); Category IV (Full Thickness tissue loss); Unstageable (Depth unknown); Deep tissue injury (suspected Deep tissue injury, Depth unknown)
Secondary Outcome Measures
Density Rate of Pressure Ulcers Category II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum (Proportion Per 1000 Bed Days, Rate)
The Incidence density of Pressure Ulcer category II, III, IV, unstageable and DTI at heels or sacrum was measured. Pressure ulcer were categorized according to the NPUAP/EPUAP 2014 classification system. The occurrence of a new Pressure ulcer of any category was assessed and documented daily during the study period. The Categories are defined as follows: Category I (nonblanchable erythema); Category II (Partial thickness Skin loss); Category III (Full Thickness Skin loss); Category IV (Full Thickness tissue loss); Unstageable (Depth unknown); Deep tissue injury (suspected Deep tissue injury, Depth unknown)
Number of Pressure Ulcer Category I (Non-blanchable Erythema) II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum (Proportion)
The the cumulative incidence of Pressure ulcer category I, II, III, IV, unstageable and DTI at heels or sacrum. Pressure ulcer were categorized according to the NPUAP/EPUAP 2014 classification system. The occurrence of a new Pressure ulcer of any category was assessed and documented daily during the study period. The Categories are defined as follows: Category I (nonblanchable erythema); Category II (Partial thickness Skin loss); Category III (Full Thickness Skin loss); Category IV (Full Thickness tissue loss); Unstageable (Depth unknown); Deep tissue injury (suspected Deep tissue injury, Depth unknown)
Number of Pressure Ulcers Category I (Non-blanchable Erythema) II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum (Proportion Per 1000 Bed Days, Rate)
The Incidence density of Pressure Ulcer category I, II, III, IV, unstageable and DTI at heels or sacrum was measured. Pressure ulcer were categorized according to the NPUAP/EPUAP 2014 classification system. The occurrence of a new Pressure ulcer of any category was assessed and documented daily during the study period. The Categories are defined as follows: Category I (nonblanchable erythema); Category II (Partial thickness Skin loss); Category III (Full Thickness Skin loss); Category IV (Full Thickness tissue loss); Unstageable (Depth unknown); Deep tissue injury (suspected Deep tissue injury, Depth unknown)
Number of Preventive Sacrum Dressings Used for Pressure Ulcer Prevention
Number of preventive sacrum dressings used for pressure ulcer prevention
Numbers of Support Surface Used for Pressure Ulcer Prevention (Total)
Support surface categories were recorded. Please see the different types in the Outcome measure data table
Time to Pressure Ulcer Development of Pressure Ulcers Category II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum
• Time to Pressure ulcer development in days
Number of Preventive Heel Dressings Used for Pressure Ulcer Prevention
Number of preventive heel dressings used for pressure ulcer prevention
Time to Pressure Ulcer Development of Pressure Ulcers Category I, II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum
• Time to Pressure ulcer development in days
Event Free Survival Time of Pressure Ulcers Category II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum (Days, Kaplan Meier Analysis)
• Estimation of the Survival function and measure of the length of time the ICU patients remained Pressure ulcer free in days
Event Free Survival Time of Pressure Ulcers Category I, II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum (Days, Kaplan Meier Analysis)
• Estimation of the Survival function and measure of the length of time the ICU patients remained Pressure ulcer free in days
Follow up Period of Included ICU Patients (Days)
Follow up period of included ICU patients in mean (days)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02295735
Brief Title
Effectiveness of Two Silicone Dressings for Sacral and Heel Pressure Ulcer Prevention
Official Title
A Randomized Controlled Parallel-group Trial to Investigate the Effectiveness of Two Silicone Dressings for Sacral and Heel Pressure Ulcer Prevention Compared to no Dressings
Study Type
Interventional
2. Study Status
Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
June 2015 (Actual)
Primary Completion Date
July 2018 (Actual)
Study Completion Date
July 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
PD Dr. Jan Kottner
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this randomized controlled trial is to test the efficacy of preventive dressings for pressure ulcer prevention.
Detailed Description
Patients of intensive acute care and residents of institutional long-term care facilities are at high risk for developing pressure ulcers (PUs). PU standard prevention includes repositioning, early mobilization and the use of special support surfaces. The use of prophylactic dressings might reduce friction and shear forces and/or modify the microclimate of the skin and might therefore protect the skin and underlying tissues from pressure/deformation injury. The primary objective of this study is to determine if preventive silicone dressings (Mepilex® border) applied to the heels and to the sacrum in addition to PU standard prevention reduces PU incidence category II, III, IV, and deep tissue injury compared to PU standard alone in at risk hospital patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pressure Ulcer
Keywords
Skin, safety, wounds, intensive care
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
475 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Mepilex® Border
Arm Type
Experimental
Arm Description
If a patient is assigned to the intervention group the dressings Mepilex® Border Sacrum and Mepilex® Border Heel will be applied onto the respective intact skin areas in addition to standard pressure ulcer prevention
Arm Title
Control
Arm Type
No Intervention
Arm Description
Standard pressure ulcer prevention according to hospital standard
Intervention Type
Device
Intervention Name(s)
Mepilex® Border Sacrum and Mepilex® Border Heel
Primary Outcome Measure Information:
Title
Number of Pressure Ulcers Category II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum (Proportion)
Description
The primary outcome was the cumulative incidence of Pressure ulcer category II, III, IV, unstageable and DTI at heels or sacrum. Pressure ulcers were categorized according to the NPUAP/EPUAP 2014 classification System. The occurrence of a new pressure ulcer of any category was assessed and documented daily during the study period. The Categories are defined as follows: Category I (nonblanchable erythema); Category II (Partial thickness Skin loss); Category III (Full Thickness Skin loss); Category IV (Full Thickness tissue loss); Unstageable (Depth unknown); Deep tissue injury (suspected Deep tissue injury, Depth unknown)
Time Frame
Duration of hospital stay, an average of 12.6 (SD +/-12.7) days
Secondary Outcome Measure Information:
Title
Density Rate of Pressure Ulcers Category II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum (Proportion Per 1000 Bed Days, Rate)
Description
The Incidence density of Pressure Ulcer category II, III, IV, unstageable and DTI at heels or sacrum was measured. Pressure ulcer were categorized according to the NPUAP/EPUAP 2014 classification system. The occurrence of a new Pressure ulcer of any category was assessed and documented daily during the study period. The Categories are defined as follows: Category I (nonblanchable erythema); Category II (Partial thickness Skin loss); Category III (Full Thickness Skin loss); Category IV (Full Thickness tissue loss); Unstageable (Depth unknown); Deep tissue injury (suspected Deep tissue injury, Depth unknown)
Time Frame
Duration of hospital stay, an average of 12.6 (SD +/-12.7) days
Title
Number of Pressure Ulcer Category I (Non-blanchable Erythema) II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum (Proportion)
Description
The the cumulative incidence of Pressure ulcer category I, II, III, IV, unstageable and DTI at heels or sacrum. Pressure ulcer were categorized according to the NPUAP/EPUAP 2014 classification system. The occurrence of a new Pressure ulcer of any category was assessed and documented daily during the study period. The Categories are defined as follows: Category I (nonblanchable erythema); Category II (Partial thickness Skin loss); Category III (Full Thickness Skin loss); Category IV (Full Thickness tissue loss); Unstageable (Depth unknown); Deep tissue injury (suspected Deep tissue injury, Depth unknown)
Time Frame
Duration of hospital stay, an average of 12.6 (SD +/-12.7) days
Title
Number of Pressure Ulcers Category I (Non-blanchable Erythema) II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum (Proportion Per 1000 Bed Days, Rate)
Description
The Incidence density of Pressure Ulcer category I, II, III, IV, unstageable and DTI at heels or sacrum was measured. Pressure ulcer were categorized according to the NPUAP/EPUAP 2014 classification system. The occurrence of a new Pressure ulcer of any category was assessed and documented daily during the study period. The Categories are defined as follows: Category I (nonblanchable erythema); Category II (Partial thickness Skin loss); Category III (Full Thickness Skin loss); Category IV (Full Thickness tissue loss); Unstageable (Depth unknown); Deep tissue injury (suspected Deep tissue injury, Depth unknown)
Time Frame
Duration of hospital stay, an average of 12.6 (SD +/-12.7) days
Title
Number of Preventive Sacrum Dressings Used for Pressure Ulcer Prevention
Description
Number of preventive sacrum dressings used for pressure ulcer prevention
Time Frame
Duration of hospital stay, an average of 12.6 (SD +/-12.7) days
Title
Numbers of Support Surface Used for Pressure Ulcer Prevention (Total)
Description
Support surface categories were recorded. Please see the different types in the Outcome measure data table
Time Frame
Duration of hospital stay, an average of 12.6 (SD +/-12.7) days
Title
Time to Pressure Ulcer Development of Pressure Ulcers Category II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum
Description
• Time to Pressure ulcer development in days
Time Frame
Duration of hospital stay, an average of 12.6 (SD +/-12.7) days
Title
Number of Preventive Heel Dressings Used for Pressure Ulcer Prevention
Description
Number of preventive heel dressings used for pressure ulcer prevention
Time Frame
Duration of hospital stay, an average of 12.6 (SD +/-12.7) days
Title
Time to Pressure Ulcer Development of Pressure Ulcers Category I, II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum
Description
• Time to Pressure ulcer development in days
Time Frame
Duration of hospital stay, an average of 12.6 (SD +/-12.7) days
Title
Event Free Survival Time of Pressure Ulcers Category II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum (Days, Kaplan Meier Analysis)
Description
• Estimation of the Survival function and measure of the length of time the ICU patients remained Pressure ulcer free in days
Time Frame
Duration of hospital stay, an average of 12.6 (SD +/-12.7) days
Title
Event Free Survival Time of Pressure Ulcers Category I, II, III, IV, Unstageable, Deep Tissue Injury (DTI) at Heels and/or Sacrum (Days, Kaplan Meier Analysis)
Description
• Estimation of the Survival function and measure of the length of time the ICU patients remained Pressure ulcer free in days
Time Frame
Duration of hospital stay, an average of 12.6 (SD +/-12.7) days
Title
Follow up Period of Included ICU Patients (Days)
Description
Follow up period of included ICU patients in mean (days)
Time Frame
Duration of hospital stay, an average of 12.6 (SD +/-12.7) days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Major trauma patients and/or critically ill patients (e.g. with cardiac arrest) admitted to the emergency department and being transferred and/or admitted directly to a surgical or internal ICU
Being at "high" or "very high" PU risk according to the Charité PU prevention standard:
- Category 3 (= partly care dependent/limited mobility in bed), 4A (= care depended, limited mobility in bed), 4B (= totally immobile) according to the Jones classification modified by Charité
Expected minimum length of stay at least three days
Informed consent (or by legal representative)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jan Kottner, PhD
Organizational Affiliation
Charite University, Berlin, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
Charité-Universitätsmedizin Berlin
City
Berlin
ZIP/Postal Code
10117
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Effectiveness of Two Silicone Dressings for Sacral and Heel Pressure Ulcer Prevention
We'll reach out to this number within 24 hrs